Pecherstorfer M, Schmoranzer F, Vesely M, Fortelny A, Baumgartner G
5. Medizinische Abteilung mit Onkologie, Krankenhaus Lainz der Stadt Wien.
Dtsch Med Wochenschr. 1990 Jul 13;115(28-29):1096-9. doi: 10.1055/s-2008-1065126.
In a 59-year-old man with multiple myeloma (kappa-light chain paraproteinaemia) in stage IIIB, bone marrow infiltration with atypical plasma cells was reduced by five cytostatic treatment courses with vincristine, melphalan, cyclophosphamide and prednisone (VMCP protocol), but anaemia requiring blood transfusion persisted (haemoglobin concentration 5.3 g/dl). Even administration of interferon alpha-2b (5 million units s.c. every other day) failed to alter this. Only a combination of interferon and erythropoietin (150 U/kg i.v. every other day) achieved lasting regression of the anaemia (haemoglobin concentration up to 14 g/dl). In four other anaemic patients with multiple myeloma, stage III, treated according to the VMCP protocol but without additional interferon, erythropoietin did not improve erythropoiesis.
一名59岁的III B期多发性骨髓瘤（κ轻链副蛋白血症）男性患者，经长春新碱、美法仑、环磷酰胺和泼尼松（VMCP方案）进行五个疗程的细胞抑制治疗后，骨髓中不典型浆细胞浸润有所减少，但仍存在需要输血的贫血症状（血红蛋白浓度为5.3 g/dl）。即使给予α-2b干扰素（隔日皮下注射500万单位）也未能改变这一情况。只有干扰素和促红细胞生成素联合使用（隔日静脉注射150 U/kg）才使贫血症状持续缓解（血红蛋白浓度高达14 g/dl）。另外四名III期多发性骨髓瘤贫血患者，按照VMCP方案治疗，但未额外使用干扰素，促红细胞生成素并未改善红细胞生成。
